Patients
anthracycline-naive, death, respiratory failure, chronic respiratory disease
RESPIRATORY FAILURE, CHRONIC RESPIRATORY DISEASE
Between March 2016 and November 2019, a total of 10 patients were enrolled and treated with doxorubicin and pembrolizumab. The trial was stopped early due to poor accrual because of difficulty in identifying patients who were anthracycline-naive. All 10 patients were included in the safety evaluation. One patient with chronic respiratory disease developed respiratory failure which led to death and was not evaluable for efficacy. Baseline patient characteristics are listed in Table Baseline patient characteristics (